The Correlation of Ten Immune Checkpoint Gene Expressions and Their Association with Gastric Cancer Development
In the immunotherapy based on immune checkpoint inhibition (IC), additional ICs are being studied to increase its effectiveness. An almost unstudied feature is the possible co-expression of ICs, which can determine the therapeutic efficacy of their inhibition. For the selection of promising ICs, inf...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/22/13846 |
| Summary: | In the immunotherapy based on immune checkpoint inhibition (IC), additional ICs are being studied to increase its effectiveness. An almost unstudied feature is the possible co-expression of ICs, which can determine the therapeutic efficacy of their inhibition. For the selection of promising ICs, information on the association of their expression with cancer development may be essential. We have obtained data on the expression correlation of <i>ADAM17</i>, <i>PVR</i>, <i>TDO2</i>, <i>CD274</i>, <i>CD276</i>, <i>CEACAM1</i>, <i>IDO1</i>, <i>LGALS3</i>, <i>LGALS9</i>, and <i>HHLA2</i> genes in gastric cancer (GC). All but one, <i>TDO2</i>, have other IC genes with co-expression at some stage. At the metastatic stage, the expression of the <i>IDO1</i> does not correlate with any other gene. The correlations are positive, but the expressions of the <i>CD276</i> and <i>CEACAM1</i> genes are negatively correlated. The expression of <i>TDO2</i> and <i>LGALS3</i> is associated with GC metastasis. The expression of <i>TDO2</i> four-fold higher in metastatic tumors than in non-metastatic tumors, but <i>LGALS3</i> was two-fold lower. The differentiation is associated with <i>IDO1</i>. The revealed features of <i>TDO2</i>, with a significant increase in expression at the metastatic stage and the absence of other IC genes with correlated expression indicates that the prospect of inhibiting <i>TDO2</i> in metastatic GC. IDO1 may be considered for inhibition in low-differentiated tumors. |
|---|---|
| ISSN: | 1661-6596 1422-0067 |